Brief: ALX Oncology’S Evorpacept Receives Fast Track Designation As First-Line Treatment For Head And Neck Squamous Cell Carcinoma

ALX Oncology Holdings

01/08/2022 13:05

Aug 1 (Reuters) - ALX Oncology Holdings Inc  ALXO.O :
    * ALX ONCOLOGY’S EVORPACEPT RECEIVES FAST TRACK DESIGNATION
FROM
FDA AS FIRST-LINE TREATMENT FOR HEAD AND NECK SQUAMOUS CELL
CARCINOMA

Source text for Eikon:  ID:nGNX82KTsb 
Further company coverage:  ALXO.O 

 ((Reuters.Briefs@thomsonreuters.com;))